4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) had its target price lowered by SVB Securities from $14.00 to $13.00 in a report released on Thursday morning, The Fly reports. Several other equities analysts also recently weighed in on FDMT. SVB Leerink reduced their price target on 4D Molecular Therapeutics from $15.00 to $14.00 and set […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) – Analysts at SVB Leerink raised their FY2024 earnings per share estimates for shares of 4D Molecular Therapeutics in a report issued on Thursday, April 13th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings of ($2.48) per share for the year, up […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) has earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) gapped down before the market opened on Thursday after SVB Securities lowered their price target on the stock from $14.00 to $13.00. The stock had previously closed at $15.16, but opened at $14.66. 4D Molecular Therapeutics shares last traded at $15.83, with a volume of […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,610,000 shares, an increase of 23.7% from the February 28th total of 2,110,000 shares. Based on an average trading volume of 343,900 shares, the short-interest ratio […]